Talis Biomedical Corporation (TLIS) | Investment Case

1. Company Snapshot

1.a. Company Description

Talis Biomedical Corporation operates as a molecular diagnostic company.The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases.It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19.

In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus.Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.

Show Full description

1.b. Last Insights on TLIS

Talis Biomedical's recent performance was driven by increased investor attention, with trading activity reaching $1.84. Although daily trading volume declined 31% to 1,356 shares, this development may indicate a shift in market sentiment. There have been no recent announcements on new products, acquisitions, or significant changes in business conditions. Additionally, no information on share buyback programs or legal issues is available. The company's most recent earnings release did not provide significant insights into its short-term prospects. (Source: Nasdaq)

1.c. Company Highlights

Last Price	1.6
Change Percentage	0.00%
Open	1.6
Previous Close	1.6
Market Cap ( Millions)	3
Volume	1677
Year High	2
Year Low	1.04
M A 50	1.58
M A 200	1.54

FCF Yield	-1842.13%
Dividend Yield	0.00%
ROE	-63.32%
Debt / Equity	28.46%
Net Debt / EBIDTA	86.40%
Price To Book	0.04
Price Earnings Ratio	-0.05
Price To FCF	-0.05
Price To sales	7.08
EV / EBITDA	0.82

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Talis Biomedical (NASDAQ:TLIS) Stock Price Up 22.7% – Should You Buy?

Oct -22

Source: defenseworld.net

North American Morning Briefing : Global Ad Shares -2-

Dec -09

Source: https://www.marketscreener.com

Why Is Talis Biomedical (TLIS) Stock Down 52% Today?

Aug -07

Source: investorplace.com

Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash

Nov -14

Source: globenewswire.com

7 Small-Cap Stocks to Sell in August Before They Crash and Burn

Aug -11

Source: InvestorPlace

Talis Biomedical Corporation (TLIS) Q2 2023 Earnings Call Transcript

Aug -10

Source: seekingalpha.com

Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update

Aug -10

Source: globenewswire.com

Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023

Aug -03

Source: GlobeNewsWire

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.00%)

6. Segments

Grant

Expected Growth: 10%

The grant from Talis Biomedical Corporation fuels growth, driven by increasing demand for innovative diagnostic solutions, strategic partnerships, and expanding research initiatives. Additionally, advancements in molecular diagnostics, growing need for point-of-care testing, and favorable regulatory environments contribute to the 10% growth rate.

Antigen Tests Products

Expected Growth: 20%

Talis Biomedical Corporation's Antigen Tests Products growth is driven by increasing demand for rapid and accurate COVID-19 testing, government investments in pandemic preparedness, and expanding point-of-care testing adoption in healthcare settings. Additionally, the company's innovative molecular diagnostic technology and strategic partnerships contribute to its 20% growth.

7. Detailed Products

Talis One

A point-of-care molecular diagnostic platform that enables rapid and accurate detection of infectious diseases

Talis AmpliFire

A molecular diagnostic system that enables rapid and accurate detection of infectious diseases, including COVID-19

Talis Assays

A range of molecular diagnostic tests for infectious diseases, including respiratory, gastrointestinal, and sexually transmitted infections

Talis Software

A cloud-based software platform that enables data management, analysis, and reporting for molecular diagnostic tests

8. Talis Biomedical Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

Talis Biomedical Corporation faces moderate threat from substitutes, as there are limited alternative products available in the market, but customers may still opt for other diagnostic methods.

Bargaining Power Of Customers

Customers have low bargaining power due to the specialized nature of Talis Biomedical Corporation's products, making it difficult for them to negotiate prices or demand customized products.

Bargaining Power Of Suppliers

Suppliers of raw materials and components have moderate bargaining power, as Talis Biomedical Corporation relies on a few key suppliers, but there are alternative sources available.

Threat Of New Entrants

The threat of new entrants is high due to the growing demand for diagnostic products and the potential for new companies to enter the market with innovative technologies.

Intensity Of Rivalry

The intensity of rivalry is high due to the presence of established competitors and the need for Talis Biomedical Corporation to differentiate its products and services to maintain market share.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	22.15%
Debt Cost	3.95%
Equity Weight	77.85%
Equity Cost	12.19%
WACC	10.36%
Leverage	28.46%

11. Quality Control: Talis Biomedical Corporation passed 5 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

LENSAR

A-Score: 5.7/10

Value: 8.8

Growth: 5.0

Quality: 5.8

Yield: 0.0

Momentum: 10.0

Volatility: 4.7

1-Year Total Return ->

Semler Scientific

A-Score: 4.9/10

Value: 7.5

Growth: 7.3

Quality: 7.2

Yield: 0.0

Momentum: 6.5

Volatility: 1.0

1-Year Total Return ->

NeuroPace

A-Score: 4.3/10

Value: 6.4

Growth: 4.8

Quality: 3.9

Yield: 0.0

Momentum: 8.5

Volatility: 2.0

1-Year Total Return ->

Quipt Home Medical

A-Score: 3.8/10

Value: 8.7

Growth: 6.7

Quality: 3.8

Yield: 0.0

Momentum: 2.5

Volatility: 1.3

1-Year Total Return ->

Talis Biomedical

A-Score: 3.7/10

Value: 8.2

Growth: 4.6

Quality: 4.4

Yield: 0.0

Momentum: 3.5

Volatility: 1.7

1-Year Total Return ->

Myomo

A-Score: 2.9/10

Value: 8.0

Growth: 4.7

Quality: 4.3

Yield: 0.0

Momentum: 0.0

Volatility: 0.7

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

13.98%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

10.36%

Talis Biomedical Corporation - US87424L2079

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on TLIS

1.c. Company Highlights

Lower Quality

Strong Momentum

Fairly Valued

Revenues Miss

Stable Momentum

Medium Volatility

Earnings Beats

Weak Momentum

Average Quality

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.00%)

6. Segments

Grant

Expected Growth: 10%

Antigen Tests Products

Expected Growth: 20%

7. Detailed Products

Talis One

Talis AmpliFire

Talis Assays

Talis Software

8. Talis Biomedical Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Talis Biomedical Corporation passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

1.6$

Current Price

1.6$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA